In conclusion, the data presented here supports a strong potential for INT-1B3 as monotherapy by triggering a long-term T cell mediated immune response against tumor antigens via the induction of immunogenic cell death and modulation of the TME. The gene discussed is INTU; the disease is neoplasm.